Defendant
1 case as defendant.
Roche Molecular Systems, Inc. (RMS) is a molecular diagnostics company and an indirect subsidiary of Roche Holding AG (SIX: ROG/RO), operating within the Roche Diagnostics division's Molecular Solutions business area. It was incorporated in 1991 to commercialize rights to polymerase chain reaction (PCR) technology acquired by Roche, and its global headquarters is at 4300 Hacienda Drive, Pleasanton, California; it also maintains a site in Branchburg, New Jersey. Roche does not publish standalone financial or headcount figures for RMS. For scale, parent Roche Holding reported 2024 group sales of CHF 60.5 billion, of which the Diagnostics division contributed CHF 14.3 billion.
RMS develops and manufactures in vitro diagnostic and blood-screening products built on PCR. Its principal offerings include the automated cobas 5800/6800/8800 high-throughput PCR systems, the point-of-care cobas liat system, and the cobas eplex and LightCycler platforms, along with sample-preparation lines such as MagNA Pure. Assay menus cover virology and infectious disease (HIV, HBV, HCV, CMV, West Nile virus, SARS-CoV-2, respiratory panels), women's health and sexual health (HPV, CT/NG), microbiology, blood-donor screening, and oncology companion diagnostics. RMS is a legal manufacturer on numerous FDA 510(k) clearances.
Litigation posture: operating company / defendant only. The tracked data shows one case, with RMS as defendant and zero plaintiff filings — the profile of a large operating diagnostics maker being targeted, not an asserter. The suit, Troll Busters LLC v. Roche Diagnostics GmbH et al. (3:11-cv-00056, S.D. Cal., filed Jan. 10, 2011, Judge Irma E. Gonzalez), was a false-marking action under 35 U.S.C. § 292 rather than a conventional infringement claim. Plaintiff Troll Busters alleged that Roche and co-defendants continued marking products with 22 expired PCR patents. It was filed in the Southern District of California, not a plaintiff-friendly Texas venue, and was voluntarily dismissed in October 2011 after the court granted motions to dismiss with leave to amend.
Co-defendants included Life Technologies, Qiagen, Thermo Fisher Scientific, Cepheid, Integrated DNA Technologies, and others — reflecting the breadth of the PCR reagent and instrument market that grew out of the foundational PCR patent estate. No other litigation appearances by RMS are recorded in the tracked data.
False marking action under 35 U.S.C. § 292 alleging defendants marked products with twenty-two expired PCR/molecular-biology patents, including US 4,889,818, after those patents had expired. The case was closed on 09/01/2011.